Oral Abuse Potential Study of Nalbuphine
A Study to Evaluate the Oral Abuse Potential of Nalbuphine Solution and Extended-Release Intact Tablets in Non-Dependent, Recreational Opioid Users
Sponsor: Syneos Health
Listed as NCT04018664, this PHASE1 trial focuses on Nalbuphine and Opioid Abuse and remains completed. Sponsored by Syneos Health, it has been updated 11 times since 2018, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
11 versions recorded-
Jun 2025 — Present [monthly]
Completed PHASE1
-
Sep 2024 — Jun 2025 [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Jan 2023 — Jul 2024 [monthly]
Completed PHASE1
-
Dec 2022 — Jan 2023 [monthly]
Completed PHASE1
▶ Show 6 earlier versions
-
Jan 2021 — Dec 2022 [monthly]
Completed PHASE1
-
Sep 2020 — Jan 2021 [monthly]
Completed PHASE1
-
Jul 2020 — Sep 2020 [monthly]
Completed PHASE1
Status: Suspended → Completed
-
Feb 2020 — Jul 2020 [monthly]
Suspended PHASE1
-
Sep 2019 — Feb 2020 [monthly]
Suspended PHASE1
-
Aug 2019 — Sep 2019 [monthly]
Suspended PHASE1
First recorded
May 2018
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Syneos Health
- Trevi Therapeutics
For direct contact, visit the study record on ClinicalTrials.gov .